Developer docs
API playgroundTry for free, no card

Search company profiles

NUVISAN GmbH

Full company profile

uuid0002ogh

Namestring
NUVISAN GmbH
Legal namestring
Nuvisan GmbH
Websiteurl
nuvisan.com
Company typeenum
Private
Founded yearint
1979
Descriptiontext

NUVISAN GmbH is a full-service contract research and manufacturing organization (CRO/CDMO) providing integrated drug discovery and development services from target identification through clinical development and GMP manufacturing. Founded in 1979 in Neu-Ulm, Germany, the company operates specialized centers of excellence in Berlin (drug discovery), Sophia Antipolis in France (formulation development and GMP manufacturing), and Neu-Ulm (bioanalysis and clinical trials clinic), with additional operational sites in Grafing and Waltrop, Germany. Service lines span five integrated modules: Discovery Services (omics and biomarkers, compound screening, pharmacology, chemistry, discovery DMPK), Preclinical Services (development DMPK, preclinical safety), Clinical Services (Phase 1 and 2, bioanalysis, biomarkers, clinical trial supply), CMC Services (drug substances, drug products, pharmaceutical analytical services, regulatory), and Digital Life Sciences (life science database, molecular modeling, cheminformatics and ML, bioinformatics). The company maintains therapeutic area specialization in oncology and dermatology, with modalities coverage including small molecules, biologics, and emerging formats such as antibody-drug conjugates.

NUVISAN operates under a professional services revenue model, with quote-based project pricing negotiated with each client on a contract basis. Customers include large and mid-sized pharmaceutical companies, biotechnology firms, venture capital portfolios, and non-profit organizations, with the Bill & Melinda Gates Foundation disclosed as a major non-profit partner via a US$25 million three-year grant for non-hormonal contraceptive research. The go-to-market motion is enterprise-focused, executed through a dedicated business development team using direct sales engagement complemented by industry conferences (SLAS Europe, CPHI, Eurotox), scientific publications, and digital channels. On April 1, 2024, NUVISAN was acquired by ALS Limited (ASX: ALQ), a public Australian diversified testing services group with operations in more than 350 locations across 55 countries, and now operates as a wholly-owned division of ALS while retaining its brand identity and leadership team.

The company is positioning for growth through three identifiable strategic vectors: AI-enabled drug discovery (participation in the €60+ million LIGAND-AI IHI consortium led by Pfizer and the Structural Genomics Consortium); women's health and global health verticals (Gates Foundation grant, Drug Discovery Innovation Challenge 2026 focused on women's health); and modality expansion via antibody-drug conjugate development (collaboration with Simris Biologics on Microcystin-based payloads). NUVISAN employs approximately 1,000 staff across five European sites, though the firmographic range indicates potential headcount of up to 5,000 within the broader ALS Group structure.

Short descriptiontext

NUVISAN GmbH is a German full-service CRO/CDMO providing integrated drug discovery, preclinical, clinical, and GMP manufacturing services to pharmaceutical, biotechnology, and non-profit clients. Founded in 1979, it operates five European sites and has been a division of ALS Limited since April 2024.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersNeu-ulm, Germany
HQ citystring
Neu-ulm
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices5 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
drug discovery services, contract research organization, preclinical development services, pharmaceutical contract manufacturing, clinical research services
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Research and Development in the Physical, Engineering, and Life Sciences54171
  • Scientific Research and Development Services5417
SIC code3 codes
  • Services-Commercial Physical & Biological Research8731
  • Pharmaceutical Preparations2834
  • Services-Medical Laboratories8071
Product category
Pharmaceutical CRO/CDMO Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Research Services (CRO)
TypeProfessional Services
Description

Providing preclinical and clinical research services on a contract basis for pharmaceutical and biotech companies conducting drug discovery and development programs.

nuvisan.com
2Contract Development and Manufacturing (CDMO)
TypeProfessional Services
Description

GMP manufacturing and formulation development services for drug substances and drug products, including analytical services and regulatory support.

nuvisan.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Nuvisan is a full-service Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) delivering integrated drug discovery and development services across Discovery (omics & biomarkers, compound screening, pharmacology, chemistry, Discovery DMPK), Preclinical (Development DMPK, preclinical safety), Clinical (Phase 1 & 2, bioanalysis, biomarkers), CMC (drug substances, drug products, pharmaceutical analytical services, regulatory support), and Digital Life Sciences (molecular modelling, cheminformatics/ML, bioinformatics & omics analysis). Services can be procured individually or as integrated end-to-end programs with therapeutic-area expertise in dermatology and oncology, executed through GLP/GMP-certified centers of excellence in Berlin, Sophia Antipolis, and Neu-Ulm.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Received US$25 million grant from Gates Foundation for non-hormonal contraceptive research
+1 more record
Product overview1 text field

Nuvisan GmbH is a full-service Contract Research Organization (CRO) and Development/Manufacturing Organization (CDMO) offering end-to-end drug discovery and development solutions. The company operates as a unified platform with interconnected service modules spanning Discovery Services (Omics & Biomarkers, Biosciences, Compound Screening, Pharmacology, Chemistry, Discovery DMPK), Preclinical Services (Development DMPK, Preclinical Safety), Clinical Services (Phase 1 & 2, Bioanalysis, Biomarkers), CMC Services (Drug Substances, Drug Products, Pharmaceutical Analytical Services, Regulatory), Digital Life Sciences (Life Science Database, Digital Science Technologies, Molecular Modelling, Cheminformatics & ML, Bioinformatics & Omics Data Analysis), and Integrated Solutions (Dermatology, Oncology, Modalities, Research Phases). The company has unique centers of excellence in Berlin (drug discovery), Sophia Antipolis (formulation and GMP manufacturing), and Neu-Ulm (bioanalysis). Services are designed to be used independently or as an integrated package, with recent AI-driven initiatives including participation in the LIGAND-AI project for AI-powered drug discovery.

Product and service6 records
1Discovery Services
CategoryDrug Discovery
Description

Comprehensive drug discovery services covering omics and biomarkers, biosciences, compound screening using 384-well plate technology, pharmacology, chemistry, and Discovery DMPK. Designed to help pharmaceutical and biotechnology clients achieve key decision milestones through deep scientific insights across multiple therapeutic areas.

2Preclinical Services
CategoryPreclinical Development
Description

Preclinical development services including Development DMPK and preclinical safety studies to successfully develop and de-risk preclinical candidates for smooth transition to clinical phases. Serves pharmaceutical and biotech clients preparing assets for first-in-human studies.

3Clinical Services
CategoryClinical Research
Description

Clinical trial services for Phase 1 and Phase 2 studies, including bioanalysis, biomarkers, and clinical trial supply services to fully assess drugs faster. Supports early-stage clinical development for pharmaceutical and biotech sponsors.

4CMC Services
CategoryPharmaceutical Development and Manufacturing
Description

Chemistry, Manufacturing, and Controls services covering drug substances, drug products, pharmaceutical analytical services, clinical trial supply, and regulatory support to advance molecules into drug products. Includes GMP manufacturing capability based at the Sophia Antipolis (Biot) center of excellence in France.

5Digital Life Sciences
CategoryDigital Life Sciences / Computational Biology
Description

Digital life sciences services including life science database, digital science technologies, molecular modelling, cheminformatics & machine learning, and bioinformatics & omics data analysis. Empowers drug discovery with integrated data services and AI for pharmaceutical and biotechnology clients.

6Integrated Solutions
CategoryIntegrated Drug Development Programs
Description

End-to-end integrated drug discovery and development solutions combining Discovery, Preclinical, Clinical, CMC, and Digital services with tailored programs across therapeutic areas including dermatology and oncology. Sold as a packaged offering where clients can outsource the full development value chain to a single scientific partner.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-01-21
Description

Innovative Health Initiative project led by Pfizer and Structural Genomics Consortium (SGC) with 18 partners across 9 countries and budget exceeding €60 million. Aims to generate large, open, high-quality datasets of protein-ligand interactions to train AI models. Nuvisan contributes to setting new benchmarks for open and standardized data generation in drug discovery.

2Simris Group AB / Simris Biologics GmbH
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2025-11-06
Description

Collaboration on preclinical ADC (Antibody-Drug Conjugate) study. Successful generation and efficacy testing of proprietary Microcystin-based payloads, with ADC variant SIMRIS-121 demonstrating full cytotoxicity against cancer cells.

pharmiweb.com
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Swiss-based global CDMO with biologics and small molecule manufacturing capabilities. Comparable in CDMO services but at significantly larger scale across multiple modalities.

TypeDirect peer
Description

Germany-headquartered contract research organization offering end-to-end drug discovery and development services spanning target identification through preclinical and clinical support. Highly comparable to Nuvisan in integrated CRO model, therapeutic area focus, and European footprint.

TypeBroad incumbent
Description

Large US-headquartered CRO/CDMO providing discovery, safety assessment, and manufacturing services. Overlaps with Nuvisan across preclinical safety, bioanalysis, and CMC but at significantly greater scale and global reach.

TypeBroad incumbent
Description

World's largest CRO with comprehensive clinical, real-world evidence, and technology-enabled services. Competes with Nuvisan's clinical Phase 1 & 2 services and broader drug development offerings.

TypeBroad incumbent
Description

Global CRO focused on clinical research and laboratory services with biopharmaceutical clients worldwide. Comparable clinical services footprint to Nuvisan's Phase 1 & 2 and bioanalysis offerings.

TypeBroad incumbent
Description

Major CRO offering early development, central labs, clinical trials, and commercialization services. Overlaps with Nuvisan in discovery, preclinical, clinical, and bioanalysis services at much larger scale.

TypeBroad incumbent
Description

Large CDMO specializing in drug substance, drug product, and clinical supply services. Directly comparable to Nuvisan's CMC offering including GMP manufacturing in Sophia Antipolis.

TypeDirect peer
Description

China-headquartered CRO/CDMO offering integrated discovery, preclinical, clinical, and manufacturing services. Comparable integrated end-to-end model though with broader geographic footprint and larger scale.

TypeBroad incumbent
Description

Global testing services group with extensive bioanalytical, central lab, and pharmaceutical services. Overlaps with Nuvisan's bioanalysis and analytical services and shares some integration logic with ALS Limited (Nuvisan's parent).

TypeOthers
Description

German bioprocessing supplier providing equipment and services for pharmaceutical manufacturing. Adjacent rather than direct competitor but shares German mid-cap life sciences positioning and biopharma customer base.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NUVISAN GmbH

Pharmaceutical CRO/CDMO Servicesnuvisan.com

NUVISAN GmbH is a German full-service CRO/CDMO providing integrated drug discovery, preclinical, clinical, and GMP manufacturing services to pharmaceutical, biotechnology, and non-profit clients. Founded in 1979, it operates five European sites and has been a division of ALS Limited since April 2024.

What NUVISAN GmbH does

NUVISAN GmbH is a full-service contract research and manufacturing organization (CRO/CDMO) providing integrated drug discovery and development services from target identification through clinical development and GMP manufacturing. Founded in 1979 in Neu-Ulm, Germany, the company operates specialized centers of excellence in Berlin (drug discovery), Sophia Antipolis in France (formulation development and GMP manufacturing), and Neu-Ulm (bioanalysis and clinical trials clinic), with additional operational sites in Grafing and Waltrop, Germany. Service lines span five integrated modules: Discovery Services (omics and biomarkers, compound screening, pharmacology, chemistry, discovery DMPK), Preclinical Services (development DMPK, preclinical safety), Clinical Services (Phase 1 and 2, bioanalysis, biomarkers, clinical trial supply), CMC Services (drug substances, drug products, pharmaceutical analytical services, regulatory), and Digital Life Sciences (life science database, molecular modeling, cheminformatics and ML, bioinformatics). The company maintains therapeutic area specialization in oncology and dermatology, with modalities coverage including small molecules, biologics, and emerging formats such as antibody-drug conjugates.

NUVISAN operates under a professional services revenue model, with quote-based project pricing negotiated with each client on a contract basis. Customers include large and mid-sized pharmaceutical companies, biotechnology firms, venture capital portfolios, and non-profit organizations, with the Bill & Melinda Gates Foundation disclosed as a major non-profit partner via a US$25 million three-year grant for non-hormonal contraceptive research. The go-to-market motion is enterprise-focused, executed through a dedicated business development team using direct sales engagement complemented by industry conferences (SLAS Europe, CPHI, Eurotox), scientific publications, and digital channels. On April 1, 2024, NUVISAN was acquired by ALS Limited (ASX: ALQ), a public Australian diversified testing services group with operations in more than 350 locations across 55 countries, and now operates as a wholly-owned division of ALS while retaining its brand identity and leadership team.

The company is positioning for growth through three identifiable strategic vectors: AI-enabled drug discovery (participation in the €60+ million LIGAND-AI IHI consortium led by Pfizer and the Structural Genomics Consortium); women's health and global health verticals (Gates Foundation grant, Drug Discovery Innovation Challenge 2026 focused on women's health); and modality expansion via antibody-drug conjugate development (collaboration with Simris Biologics on Microcystin-based payloads). NUVISAN employs approximately 1,000 staff across five European sites, though the firmographic range indicates potential headcount of up to 5,000 within the broader ALS Group structure.

NUVISAN GmbH firmographics

Firmographics
Name
NUVISAN GmbH
Legal name
Nuvisan GmbH
Website
https://nuvisan.com
Company type
Private
Founded year
1979
Operating status
Operating
Headcount range
501–1,000 employees
Short description
NUVISAN GmbH is a German full-service CRO/CDMO providing integrated drug discovery, preclinical, clinical, and GMP manufacturing services to pharmaceutical, biotechnology, and non-profit clients. Founded in 1979, it operates five European sites and has been a division of ALS Limited since April 2024.
Ownership category
akta.pro rank

NUVISAN GmbH industry classification

Industry
Product category
Pharmaceutical CRO/CDMO Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)
SIC
Services-Commercial Physical & Biological Research (8731), Pharmaceutical Preparations (2834), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Drug discovery services
  • Contract research organization
  • Preclinical development services
  • Pharmaceutical contract manufacturing
  • Clinical research services

Where NUVISAN GmbH is headquartered

Location

Headquarters

HQ city
Neu-ulm
HQ country
Germany
HQ region
Europe

Offices5 records

Markets served

NUVISAN GmbH business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Contract Research Services (CRO): Providing preclinical and clinical research services on a contract basis for pharmaceutical and biotech companies conducting drug discovery and development programs.
  2. Contract Development and Manufacturing (CDMO): GMP manufacturing and formulation development services for drug substances and drug products, including analytical services and regulatory support.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

NUVISAN GmbH product offering

Product offering

Core offering

Nuvisan is a full-service Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) delivering integrated drug discovery and development services across Discovery (omics & biomarkers, compound screening, pharmacology, chemistry, Discovery DMPK), Preclinical (Development DMPK, preclinical safety), Clinical (Phase 1 & 2, bioanalysis, biomarkers), CMC (drug substances, drug products, pharmaceutical analytical services, regulatory support), and Digital Life Sciences (molecular modelling, cheminformatics/ML, bioinformatics & omics analysis). Services can be procured individually or as integrated end-to-end programs with therapeutic-area expertise in dermatology and oncology, executed through GLP/GMP-certified centers of excellence in Berlin, Sophia Antipolis, and Neu-Ulm.

Product overview

Nuvisan GmbH is a full-service Contract Research Organization (CRO) and Development/Manufacturing Organization (CDMO) offering end-to-end drug discovery and development solutions. The company operates as a unified platform with interconnected service modules spanning Discovery Services (Omics & Biomarkers, Biosciences, Compound Screening, Pharmacology, Chemistry, Discovery DMPK), Preclinical Services (Development DMPK, Preclinical Safety), Clinical Services (Phase 1 & 2, Bioanalysis, Biomarkers), CMC Services (Drug Substances, Drug Products, Pharmaceutical Analytical Services, Regulatory), Digital Life Sciences (Life Science Database, Digital Science Technologies, Molecular Modelling, Cheminformatics & ML, Bioinformatics & Omics Data Analysis), and Integrated Solutions (Dermatology, Oncology, Modalities, Research Phases). The company has unique centers of excellence in Berlin (drug discovery), Sophia Antipolis (formulation and GMP manufacturing), and Neu-Ulm (bioanalysis). Services are designed to be used independently or as an integrated package, with recent AI-driven initiatives including participation in the LIGAND-AI project for AI-powered drug discovery.

Differentiator

Problem solved

Functional benefit

Products and services

  • Discovery Services Comprehensive drug discovery services covering omics and biomarkers, biosciences, compound screening using 384-well plate technology, pharmacology, chemistry, and Discovery DMPK. Designed to help pharmaceutical and biotechnology clients achieve key decision milestones through deep scientific insights across multiple therapeutic areas.
  • Preclinical Services Preclinical development services including Development DMPK and preclinical safety studies to successfully develop and de-risk preclinical candidates for smooth transition to clinical phases. Serves pharmaceutical and biotech clients preparing assets for first-in-human studies.
  • Clinical Services Clinical trial services for Phase 1 and Phase 2 studies, including bioanalysis, biomarkers, and clinical trial supply services to fully assess drugs faster. Supports early-stage clinical development for pharmaceutical and biotech sponsors.
  • CMC Services Chemistry, Manufacturing, and Controls services covering drug substances, drug products, pharmaceutical analytical services, clinical trial supply, and regulatory support to advance molecules into drug products. Includes GMP manufacturing capability based at the Sophia Antipolis (Biot) center of excellence in France.
  • Digital Life Sciences Digital life sciences services including life science database, digital science technologies, molecular modelling, cheminformatics & machine learning, and bioinformatics & omics data analysis. Empowers drug discovery with integrated data services and AI for pharmaceutical and biotechnology clients.
  • Integrated Solutions End-to-end integrated drug discovery and development solutions combining Discovery, Preclinical, Clinical, CMC, and Digital services with tailored programs across therapeutic areas including dermatology and oncology. Sold as a packaged offering where clients can outsource the full development value chain to a single scientific partner.

Quantifiable outcome

  • Received US$25 million grant from Gates Foundation for non-hormonal contraceptive research
  • +1 more outcomes

Companies that use NUVISAN GmbH

Customer profile

Named customers4 records

Segments1 record

Ideal customer profiles4 records

NUVISAN GmbH technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability10 records

Feature5 records

NUVISAN GmbH partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered flagship and minor.

  • LIGAND-AI (IHI Project)flagshipStrategic or Co-development Partner · 21 January 2026Innovative Health Initiative project led by Pfizer and Structural Genomics Consortium (SGC) with 18 partners across 9 countries and budget exceeding €60 million. Aims to generate large, open, high-quality datasets of protein-ligand interactions to train AI models. Nuvisan contributes to setting new benchmarks for open and standardized data generation in drug discovery.
  • Simris Group AB / Simris Biologics GmbHminorStrategic or Co-development Partner · 6 November 2025Collaboration on preclinical ADC (Antibody-Drug Conjugate) study. Successful generation and efficacy testing of proprietary Microcystin-based payloads, with ADC variant SIMRIS-121 demonstrating full cytotoxicity against cancer cells.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

NUVISAN GmbH competitors and assessment

Company assessment

Broad incumbents

  • Lonza Group: Swiss-based global CDMO with biologics and small molecule manufacturing capabilities. Comparable in CDMO services but at significantly larger scale across multiple modalities.
  • Charles River Laboratories: Large US-headquartered CRO/CDMO providing discovery, safety assessment, and manufacturing services. Overlaps with Nuvisan across preclinical safety, bioanalysis, and CMC but at significantly greater scale and global reach.
  • IQVIA: World's largest CRO with comprehensive clinical, real-world evidence, and technology-enabled services. Competes with Nuvisan's clinical Phase 1 & 2 services and broader drug development offerings.
  • ICON plc: Global CRO focused on clinical research and laboratory services with biopharmaceutical clients worldwide. Comparable clinical services footprint to Nuvisan's Phase 1 & 2 and bioanalysis offerings.
  • Labcorp Drug Development (formerly Covance): Major CRO offering early development, central labs, clinical trials, and commercialization services. Overlaps with Nuvisan in discovery, preclinical, clinical, and bioanalysis services at much larger scale.
  • Catalent (Novo Holdings): Large CDMO specializing in drug substance, drug product, and clinical supply services. Directly comparable to Nuvisan's CMC offering including GMP manufacturing in Sophia Antipolis.
  • Eurofins Scientific: Global testing services group with extensive bioanalytical, central lab, and pharmaceutical services. Overlaps with Nuvisan's bioanalysis and analytical services and shares some integration logic with ALS Limited (Nuvisan's parent).

Direct peers

  • Evotec SE: Germany-headquartered contract research organization offering end-to-end drug discovery and development services spanning target identification through preclinical and clinical support. Highly comparable to Nuvisan in integrated CRO model, therapeutic area focus, and European footprint.
  • WuXi AppTec: China-headquartered CRO/CDMO offering integrated discovery, preclinical, clinical, and manufacturing services. Comparable integrated end-to-end model though with broader geographic footprint and larger scale.

Others

  • Sartorius AG: German bioprocessing supplier providing equipment and services for pharmaceutical manufacturing. Adjacent rather than direct competitor but shares German mid-cap life sciences positioning and biopharma customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

NUVISAN GmbH social profiles

Digital presence

NUVISAN GmbH financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NUVISAN GmbH leadership team

Management profile

Number of profiles

Profiles8 records

NUVISAN GmbH funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NUVISAN GmbH M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NUVISAN GmbH

What does NUVISAN GmbH do?

Nuvisan is a full-service Contract Research Organization (CRO) and Contract Development and Manufacturing Organization (CDMO) delivering integrated drug discovery and development services across Discovery (omics & biomarkers, compound screening, pharmacology, chemistry, Discovery DMPK), Preclinical (Development DMPK, preclinical safety), Clinical (Phase 1 & 2, bioanalysis, biomarkers), CMC (drug substances, drug products, pharmaceutical analytical services, regulatory support), and Digital Life Sciences (molecular modelling, cheminformatics/ML, bioinformatics & omics analysis). Services can be procured individually or as integrated end-to-end programs with therapeutic-area expertise in dermatology and oncology, executed through GLP/GMP-certified centers of excellence in Berlin, Sophia Antipolis, and Neu-Ulm.

Is NUVISAN GmbH a public or private company?

NUVISAN GmbH is a private company. It is classified as corporate owned and is currently operating.

When was NUVISAN GmbH founded?

NUVISAN GmbH was founded in 1979. It employs 501 to 1,000 people.

Where is NUVISAN GmbH based?

NUVISAN GmbH is headquartered in Neu-ulm, Germany, in the Europe region.

How does NUVISAN GmbH make money?

Two revenue lines are on record. Contract Research Services (CRO) is the primary driver. The others are contract Development and Manufacturing (CDMO).

Who are NUVISAN GmbH's main competitors?

Broad incumbents on record are Lonza Group, Charles River Laboratories, IQVIA, ICON plc, Labcorp Drug Development (formerly Covance), Catalent (Novo Holdings) and Eurofins Scientific. Direct peers are Evotec SE and WuXi AppTec. Sartorius AG is listed as an others.

Does NUVISAN GmbH have an API?

No public API is recorded for NUVISAN GmbH.

What industry is NUVISAN GmbH in?

NUVISAN GmbH's product category is Pharmaceutical CRO/CDMO Services. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAK, Clinical Trial Material (CTM) Manufacturing & Supply CDMO. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PharmiWeb.comSimris Group AB Announces Positive Results from Ongoing Antibody-Drug Conjugate (ADC) Study with NuvisanSimris Group AB's wholly owned subsidiary Simris Biologics GmbH announced positive preclinical results from an ongoing ADC study with Nuvisan, where one of three proprietary Microcystin-based ADC variants demonstrated full cytotoxicity against antigen-expressing cancer cell lines in two independent in-vitro trials. The lead payload candidate, designated SIMRIS-121, will advance to dose-escalation in-vivo studies in mice to determine the maximum tolerated dose. The results support Simris' broader mission to develop cyanobacteria-derived toxin payloads for next-generation antibody-drug conjugates.Uni-muensterChemist Ryan Gilmour receives "ERC Proof of Concept Grant"Ryan Gilmour, a chemist at the University of Münster, received a 150,000-euro ERC Proof of Concept Grant to commercialize his strategy for producing fluorinated molecular building blocks. The grant supports making his research commercially viable, with partners including Merck, Novartis, and Nuvisan. He will explore methods to bring the technology to market.PR NewswireNUVISAN receives US$9.6m grant for a multi-target drug discovery program on novel non-hormonal contraceptive medicinesNUVISAN ICB GmbH, a contract research and development provider, announced on September 20, 2022 that it received a three-year, US$9.6 million grant from the Bill & Melinda Gates Foundation to develop non-hormonal contraceptive medicines. The program will screen up to 2.46 million compounds and optimize hits into in vivo lead compounds. NUVISAN said no further details were disclosed.PR NewswireHoth Therapeutics Announces the selection of NUVISAN for Manufacturing HT-001 Drug Batches for CLEER-001 Clinical Study for Cancer PatientsHoth Therapeutics announced it has signed an agreement with NUVISAN, a European CRO/CDMO with topical manufacturing capabilities in Sophia-Antipolis, France, to manufacture clinical batches of HT-001 topical drug product for its upcoming CLEER-001 phase 2a clinical trial for cancer patients. HT-001 is a novel topical therapy in development for treating cutaneous toxicities associated with Epidermal Growth Factor Receptor (EGFR) inhibitor cancer therapy. The randomized, placebo-controlled study is planned to include 14 clinical sites in the United States.